)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
Vaxcyte
Vaxcyte (PCVX) investor relations material
Vaxcyte Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary12 Feb, 2026
Strategic focus and market opportunity
Pneumococcal conjugate vaccines are the primary focus, addressing a historically significant cause of death with improved technology for broader coverage and immunogenicity.
The market is valued at $8 billion and is expected to grow, especially as adult vaccination rates increase globally.
Expansion beyond the U.S. is a priority, with evolving recommendations for adult vaccination in multiple countries and a new Chief Commercial Officer to guide global strategy.
Selective commercialization and partnerships are planned to maximize reach, particularly for the infant segment.
The adult market is projected to reach $4–5 billion, with catch-up cohorts and expanded age recommendations driving growth.
Clinical development and regulatory strategy
Phase 3 program for VAX-31 launched after strong phase 2 data, showing improved immune responses with expanded serotype coverage.
The pivotal OPUS-1 study involves 4,000 adults aged 50+, comparing VAX-31 to current standards with higher non-inferiority thresholds.
Additional studies include co-administration with flu vaccines and evaluation in previously vaccinated adults, with a manufacturing consistency study planned.
Regulatory standards have shifted from a 0.5 to 0.67 non-inferiority threshold, but historical predictability in this vaccine class is high.
The pivotal study includes both 50–64 and 65+ age groups, reflecting recent changes in universal vaccination recommendations.
Competitive landscape and product differentiation
VAX-31 aims to surpass current vaccines (Prevnar 20 and CAPVAXIVE) by covering both older and newer serotypes, offering a singular, broad-spectrum solution.
CAPVAXIVE has gained rapid market share due to broader coverage, but VAX-31 is positioned to become the next preferred recommendation if data supports its profile.
The pivotal study compares VAX-31 to both competitors across overlapping and unique serotypes, with analytical flexibility for trade-offs in immune response.
FDA acknowledges the trade-off between coverage and immune response, with VAX-31 data providing reassurance.
Market share shifts are driven by coverage breadth, and VAX-31 could become the next incremental recommendation.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Vaxcyte earnings date
Q4 202524 Feb, 2026
Vaxcyte
Next Vaxcyte earnings date
Q4 202524 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Vaxcyte Inc. is a clinical-stage biotechnology company focused on the development of novel protein vaccines aimed at preventing or treating bacterial infectious diseases. Its leading vaccine candidate, VAX-24, is a 24-valent investigational pneumococcal conjugate vaccine designed to prevent invasive pneumococcal disease. In addition to VAX-24, Vaxcyte is working on several other vaccine candidates, including VAX-31, to address emerging strains and antibiotic resistance; VAX-A1, targeting Group A Streptococcus; VAX-PG, aimed at a keystone pathogen responsible for periodontitis; and VAX-GI, to prevent Shigella. The company is headquartered in San Carlos, California and its shares are listed on the NASDAQ stock exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage